Nothing Special   »   [go: up one dir, main page]

Zimmermann et al., 2013 - Google Patents

Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

Zimmermann et al., 2013

View PDF
Document ID
320232907755001200
Author
Zimmermann G
Papke B
Ismail S
Vartak N
Chandra A
Hoffmann M
Hahn S
Triola G
Wittinghofer A
Bastiaens P
Waldmann H
Publication year
Publication venue
Nature

External Links

Snippet

The KRAS oncogene product is considered a major target in anticancer drug discovery,,. However, direct interference with KRAS signalling has not yet led to clinically useful drugs,,,,,. Correct localization and signalling by farnesylated KRAS is regulated by the prenyl …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Similar Documents

Publication Publication Date Title
Zimmermann et al. Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Momcilovic et al. In vivo imaging of mitochondrial membrane potential in non-small-cell lung cancer
Carvalho et al. ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma
Kim et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
Faivre et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
Nowak et al. Plasticity in binding confers selectivity in ligand-induced protein degradation
Khandelwal et al. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor
Wu et al. A chemical toolbox for the study of bromodomains and epigenetic signaling
Dar et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
Yan et al. Discovery and characterization of small molecules that target the GTPase Ral
Papke et al. Identification of pyrazolopyridazinones as PDEδ inhibitors
Lin et al. SPA70 is a potent antagonist of human pregnane X receptor
Rochel et al. Recurrent activating mutations of PPARγ associated with luminal bladder tumors
Watts et al. Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes
Ciceri et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Patel et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2
Torrance et al. Use of isogenic human cancer cells for high-throughput screening and drug discovery
Chen et al. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons
Beyett et al. Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors
Zhang et al. Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters
Babu et al. Phosphoproteomic analysis identifies CLK1 as a novel therapeutic target in gastric cancer
Kosakowska-Cholody et al. HKH40A downregulates GRP78/BiP expression in cancer cells
Alshareef et al. The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers
Senisterra et al. Discovery of small-molecule antagonists of the H3K9me3 binding to UHRF1 tandem tudor domain
Bais et al. Effects of tumor-suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and its direct interactions with DNA repair pathways